Limitations and opportunities in the pharmacotherapy of ciliopathies
Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such a...
Gespeichert in:
Veröffentlicht in: | Pharmacology & therapeutics (Oxford) 2021-09, Vol.225, p.107841-107841, Article 107841 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 107841 |
---|---|
container_issue | |
container_start_page | 107841 |
container_title | Pharmacology & therapeutics (Oxford) |
container_volume | 225 |
creator | Duong Phu, Max Bross, Stefan Burkhalter, Martin D. Philipp, Melanie |
description | Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies. |
doi_str_mv | 10.1016/j.pharmthera.2021.107841 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2506278488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725821000437</els_id><sourcerecordid>2506278488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</originalsourceid><addsrcrecordid>eNqFkE1LwzAYgIMobk7_guTopTNp2iY96pwfMPCi4C1k-WAZbVOTVNi_N1unHj298PK8ecgDAMRojhGubrfzfiN8Gzfai3mOcpzWlBX4BEwxo3WWmI9TME2DZDQv2QRchLBFCBUFys_BhBBKccnIFDysbGujiNZ1AYpOQdf3zsehs9HqAG0HkwQebEK6g7DfQWegtI11vYibhF2CMyOaoK-OcwbeH5dvi-ds9fr0srhbZbLIi5gRQ2pM8VpJqgxhqJIGV5WsqdKmVqikUmImJCVpK7RApBakrApaGEoVUoLMwM34bu_d56BD5K0NUjeN6LQbAs9LVOWpA2MJZSMqvQvBa8N7b1vhdxwjvm_It_yvId835GPDdHp9tAzrVqvfw59oCbgfAZ3--mW150Fa3UmtrNcycuXs_5ZvAfWI2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506278488</pqid></control><display><type>article</type><title>Limitations and opportunities in the pharmacotherapy of ciliopathies</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Duong Phu, Max ; Bross, Stefan ; Burkhalter, Martin D. ; Philipp, Melanie</creator><creatorcontrib>Duong Phu, Max ; Bross, Stefan ; Burkhalter, Martin D. ; Philipp, Melanie</creatorcontrib><description>Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2021.107841</identifier><identifier>PMID: 33771583</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Autosomal dominant polycystic kidney disease ; Cilia ; Ciliopathies - drug therapy ; Ciliopathy ; Humans ; Primary cilia dyskinesia ; Retinopathies</subject><ispartof>Pharmacology & therapeutics (Oxford), 2021-09, Vol.225, p.107841-107841, Article 107841</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</citedby><cites>FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pharmthera.2021.107841$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33771583$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duong Phu, Max</creatorcontrib><creatorcontrib>Bross, Stefan</creatorcontrib><creatorcontrib>Burkhalter, Martin D.</creatorcontrib><creatorcontrib>Philipp, Melanie</creatorcontrib><title>Limitations and opportunities in the pharmacotherapy of ciliopathies</title><title>Pharmacology & therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.</description><subject>Autosomal dominant polycystic kidney disease</subject><subject>Cilia</subject><subject>Ciliopathies - drug therapy</subject><subject>Ciliopathy</subject><subject>Humans</subject><subject>Primary cilia dyskinesia</subject><subject>Retinopathies</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LwzAYgIMobk7_guTopTNp2iY96pwfMPCi4C1k-WAZbVOTVNi_N1unHj298PK8ecgDAMRojhGubrfzfiN8Gzfai3mOcpzWlBX4BEwxo3WWmI9TME2DZDQv2QRchLBFCBUFys_BhBBKccnIFDysbGujiNZ1AYpOQdf3zsehs9HqAG0HkwQebEK6g7DfQWegtI11vYibhF2CMyOaoK-OcwbeH5dvi-ds9fr0srhbZbLIi5gRQ2pM8VpJqgxhqJIGV5WsqdKmVqikUmImJCVpK7RApBakrApaGEoVUoLMwM34bu_d56BD5K0NUjeN6LQbAs9LVOWpA2MJZSMqvQvBa8N7b1vhdxwjvm_It_yvId835GPDdHp9tAzrVqvfw59oCbgfAZ3--mW150Fa3UmtrNcycuXs_5ZvAfWI2A</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Duong Phu, Max</creator><creator>Bross, Stefan</creator><creator>Burkhalter, Martin D.</creator><creator>Philipp, Melanie</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202109</creationdate><title>Limitations and opportunities in the pharmacotherapy of ciliopathies</title><author>Duong Phu, Max ; Bross, Stefan ; Burkhalter, Martin D. ; Philipp, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Autosomal dominant polycystic kidney disease</topic><topic>Cilia</topic><topic>Ciliopathies - drug therapy</topic><topic>Ciliopathy</topic><topic>Humans</topic><topic>Primary cilia dyskinesia</topic><topic>Retinopathies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duong Phu, Max</creatorcontrib><creatorcontrib>Bross, Stefan</creatorcontrib><creatorcontrib>Burkhalter, Martin D.</creatorcontrib><creatorcontrib>Philipp, Melanie</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology & therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duong Phu, Max</au><au>Bross, Stefan</au><au>Burkhalter, Martin D.</au><au>Philipp, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limitations and opportunities in the pharmacotherapy of ciliopathies</atitle><jtitle>Pharmacology & therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2021-09</date><risdate>2021</risdate><volume>225</volume><spage>107841</spage><epage>107841</epage><pages>107841-107841</pages><artnum>107841</artnum><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>33771583</pmid><doi>10.1016/j.pharmthera.2021.107841</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-7258 |
ispartof | Pharmacology & therapeutics (Oxford), 2021-09, Vol.225, p.107841-107841, Article 107841 |
issn | 0163-7258 1879-016X |
language | eng |
recordid | cdi_proquest_miscellaneous_2506278488 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Autosomal dominant polycystic kidney disease Cilia Ciliopathies - drug therapy Ciliopathy Humans Primary cilia dyskinesia Retinopathies |
title | Limitations and opportunities in the pharmacotherapy of ciliopathies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A03%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limitations%20and%20opportunities%20in%20the%20pharmacotherapy%20of%20ciliopathies&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Duong%20Phu,%20Max&rft.date=2021-09&rft.volume=225&rft.spage=107841&rft.epage=107841&rft.pages=107841-107841&rft.artnum=107841&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2021.107841&rft_dat=%3Cproquest_cross%3E2506278488%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506278488&rft_id=info:pmid/33771583&rft_els_id=S0163725821000437&rfr_iscdi=true |